Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer
Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line -paclitaxel ± durvalumab. Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of C...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2020-04, Vol.16 (12), p.749-762 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 762 |
|---|---|
| container_issue | 12 |
| container_start_page | 749 |
| container_title | Future oncology (London, England) |
| container_volume | 16 |
| creator | Ponce Aix, Santiago Talbot, Denis Govindan, Ramaswamy Dols, Manuel Cobo Postmus, Pieter E Lewanski, Conrad Bennouna, Jaafar Fischer, Juergen R Juan-Vidal, Oscar Stewart, David J Ardizzoni, Andrea Bhore, Rafia Wolfsteiner, Marianne Reck, Martin Ong, Teng Jin Morgensztern, Daniel |
| description | Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line
-paclitaxel ± durvalumab.
Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core.
QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [
-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [
-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively.
While QoL trends were promising, additional data are required to support these regimens in this setting. |
| doi_str_mv | 10.2217/fon-2019-0796 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_fon_2019_0796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32228198</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-ccb66abf02a7b2cd59f1ec4d032a61d9c81987f712d29839c525928072c24f853</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhoMotlaPXiV_IJrMfiQ5StEqFETQ85LNRxvJZkuyVfvv3aXqaYZ5H4aXB6FrRm8BGL9zfSRAmSSUy_oEzRkvSyIKyk7HveSS1LUsZ-gi5w9KS15U9BzNCgAQTIo56l_3KvjhgHuHg3cWf_lhi7PVfTS4T3jY-mTGJFocVYvJTukRV982kFZla3CyG9_ZmLGPWJlPFfV4jGOp3KkQiLYh4LCPG6ynKF2iM6dCtle_c4HeHx_elk9k_bJ6Xt6viQYhBqJ1W9eqdRQUb0GbSjpmdWloAapmRuqpPXecgQEpCqkrqCQIykFD6URVLBA5_tWpzzlZ1-yS71Q6NIw2k7hmFNdM4ppJ3MjfHPndvu2s-af_TBU_R31qKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer</title><source>MEDLINE</source><source>PubMed Central</source><creator>Ponce Aix, Santiago ; Talbot, Denis ; Govindan, Ramaswamy ; Dols, Manuel Cobo ; Postmus, Pieter E ; Lewanski, Conrad ; Bennouna, Jaafar ; Fischer, Juergen R ; Juan-Vidal, Oscar ; Stewart, David J ; Ardizzoni, Andrea ; Bhore, Rafia ; Wolfsteiner, Marianne ; Reck, Martin ; Ong, Teng Jin ; Morgensztern, Daniel</creator><creatorcontrib>Ponce Aix, Santiago ; Talbot, Denis ; Govindan, Ramaswamy ; Dols, Manuel Cobo ; Postmus, Pieter E ; Lewanski, Conrad ; Bennouna, Jaafar ; Fischer, Juergen R ; Juan-Vidal, Oscar ; Stewart, David J ; Ardizzoni, Andrea ; Bhore, Rafia ; Wolfsteiner, Marianne ; Reck, Martin ; Ong, Teng Jin ; Morgensztern, Daniel</creatorcontrib><description>Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line
-paclitaxel ± durvalumab.
Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core.
QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [
-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [
-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively.
While QoL trends were promising, additional data are required to support these regimens in this setting.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2019-0796</identifier><identifier>PMID: 32228198</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Albumins - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Paclitaxel - administration & dosage ; Quality of Life ; Retreatment ; Treatment Outcome</subject><ispartof>Future oncology (London, England), 2020-04, Vol.16 (12), p.749-762</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c288t-ccb66abf02a7b2cd59f1ec4d032a61d9c81987f712d29839c525928072c24f853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32228198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ponce Aix, Santiago</creatorcontrib><creatorcontrib>Talbot, Denis</creatorcontrib><creatorcontrib>Govindan, Ramaswamy</creatorcontrib><creatorcontrib>Dols, Manuel Cobo</creatorcontrib><creatorcontrib>Postmus, Pieter E</creatorcontrib><creatorcontrib>Lewanski, Conrad</creatorcontrib><creatorcontrib>Bennouna, Jaafar</creatorcontrib><creatorcontrib>Fischer, Juergen R</creatorcontrib><creatorcontrib>Juan-Vidal, Oscar</creatorcontrib><creatorcontrib>Stewart, David J</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><creatorcontrib>Bhore, Rafia</creatorcontrib><creatorcontrib>Wolfsteiner, Marianne</creatorcontrib><creatorcontrib>Reck, Martin</creatorcontrib><creatorcontrib>Ong, Teng Jin</creatorcontrib><creatorcontrib>Morgensztern, Daniel</creatorcontrib><title>Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line
-paclitaxel ± durvalumab.
Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core.
QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [
-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [
-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively.
While QoL trends were promising, additional data are required to support these regimens in this setting.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Albumins - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paclitaxel - administration & dosage</subject><subject>Quality of Life</subject><subject>Retreatment</subject><subject>Treatment Outcome</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LAzEQhoMotlaPXiV_IJrMfiQ5StEqFETQ85LNRxvJZkuyVfvv3aXqaYZ5H4aXB6FrRm8BGL9zfSRAmSSUy_oEzRkvSyIKyk7HveSS1LUsZ-gi5w9KS15U9BzNCgAQTIo56l_3KvjhgHuHg3cWf_lhi7PVfTS4T3jY-mTGJFocVYvJTukRV982kFZla3CyG9_ZmLGPWJlPFfV4jGOp3KkQiLYh4LCPG6ynKF2iM6dCtle_c4HeHx_elk9k_bJ6Xt6viQYhBqJ1W9eqdRQUb0GbSjpmdWloAapmRuqpPXecgQEpCqkrqCQIykFD6URVLBA5_tWpzzlZ1-yS71Q6NIw2k7hmFNdM4ppJ3MjfHPndvu2s-af_TBU_R31qKg</recordid><startdate>202004</startdate><enddate>202004</enddate><creator>Ponce Aix, Santiago</creator><creator>Talbot, Denis</creator><creator>Govindan, Ramaswamy</creator><creator>Dols, Manuel Cobo</creator><creator>Postmus, Pieter E</creator><creator>Lewanski, Conrad</creator><creator>Bennouna, Jaafar</creator><creator>Fischer, Juergen R</creator><creator>Juan-Vidal, Oscar</creator><creator>Stewart, David J</creator><creator>Ardizzoni, Andrea</creator><creator>Bhore, Rafia</creator><creator>Wolfsteiner, Marianne</creator><creator>Reck, Martin</creator><creator>Ong, Teng Jin</creator><creator>Morgensztern, Daniel</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202004</creationdate><title>Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer</title><author>Ponce Aix, Santiago ; Talbot, Denis ; Govindan, Ramaswamy ; Dols, Manuel Cobo ; Postmus, Pieter E ; Lewanski, Conrad ; Bennouna, Jaafar ; Fischer, Juergen R ; Juan-Vidal, Oscar ; Stewart, David J ; Ardizzoni, Andrea ; Bhore, Rafia ; Wolfsteiner, Marianne ; Reck, Martin ; Ong, Teng Jin ; Morgensztern, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-ccb66abf02a7b2cd59f1ec4d032a61d9c81987f712d29839c525928072c24f853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Albumins - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paclitaxel - administration & dosage</topic><topic>Quality of Life</topic><topic>Retreatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ponce Aix, Santiago</creatorcontrib><creatorcontrib>Talbot, Denis</creatorcontrib><creatorcontrib>Govindan, Ramaswamy</creatorcontrib><creatorcontrib>Dols, Manuel Cobo</creatorcontrib><creatorcontrib>Postmus, Pieter E</creatorcontrib><creatorcontrib>Lewanski, Conrad</creatorcontrib><creatorcontrib>Bennouna, Jaafar</creatorcontrib><creatorcontrib>Fischer, Juergen R</creatorcontrib><creatorcontrib>Juan-Vidal, Oscar</creatorcontrib><creatorcontrib>Stewart, David J</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><creatorcontrib>Bhore, Rafia</creatorcontrib><creatorcontrib>Wolfsteiner, Marianne</creatorcontrib><creatorcontrib>Reck, Martin</creatorcontrib><creatorcontrib>Ong, Teng Jin</creatorcontrib><creatorcontrib>Morgensztern, Daniel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ponce Aix, Santiago</au><au>Talbot, Denis</au><au>Govindan, Ramaswamy</au><au>Dols, Manuel Cobo</au><au>Postmus, Pieter E</au><au>Lewanski, Conrad</au><au>Bennouna, Jaafar</au><au>Fischer, Juergen R</au><au>Juan-Vidal, Oscar</au><au>Stewart, David J</au><au>Ardizzoni, Andrea</au><au>Bhore, Rafia</au><au>Wolfsteiner, Marianne</au><au>Reck, Martin</au><au>Ong, Teng Jin</au><au>Morgensztern, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2020-04</date><risdate>2020</risdate><volume>16</volume><issue>12</issue><spage>749</spage><epage>762</epage><pages>749-762</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line
-paclitaxel ± durvalumab.
Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core.
QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [
-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [
-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively.
While QoL trends were promising, additional data are required to support these regimens in this setting.</abstract><cop>England</cop><pmid>32228198</pmid><doi>10.2217/fon-2019-0796</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2020-04, Vol.16 (12), p.749-762 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_crossref_primary_10_2217_fon_2019_0796 |
| source | MEDLINE; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Albumins - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Paclitaxel - administration & dosage Quality of Life Retreatment Treatment Outcome |
| title | Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A00%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20with%20second%20or%20third%20line%20nab%20-paclitaxel-based%20regimens%20in%20advanced%20non-small-cell%20lung%20cancer&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Ponce%20Aix,%20Santiago&rft.date=2020-04&rft.volume=16&rft.issue=12&rft.spage=749&rft.epage=762&rft.pages=749-762&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2019-0796&rft_dat=%3Cpubmed_cross%3E32228198%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32228198&rfr_iscdi=true |